Corporate & Investor Presentation

Track record of strong financial returns for shareholders (Financial data as of March 31, 2022) $2.0 Revenue ($B) 12% CAGR $3.5 LTM 3Q17 LTM 3Q22 Non-GAAP Operating Income ($M) $504 16% CAGR $1,062 LTM 3Q17 LTM 3Q22 Non-GAAP EPS $2.80 15% CAGR $5.65 LTM 3Q17 LTM 3Q22 Total shareholder return, TSR (NYSE shares as of 03/31/2022): 1-yr 26% | 3-yr 139% NOTE: See reconciliation to GAAP in Appendix | 5-yr 255% 30 © 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed

View entire presentation